Antihistamine Drugs Market Share

Global Antihistamine Drugs Market Overview

Antihistamine Drugs Market Size was valued at USD 0.16 Billion in 2023. The Antihistamine Drugs market industry is projected to grow from USD 0.17 Billion in 2024 to USD 0.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.60% during the forecast period (2024 - 2032).Raising awareness about allergy-related therapies and the rising rate of Allergic rhinitis are the key market drivers contributing to the market’s growth and expansion. 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Anti-allergic drugs called antihistamines are used to treat several allergies. Additionally, these drugs are used to treat anxiety, motion sickness, and insomnia. The market is expanding as a result of more research and development activity. This will present advantageous chances for the market for antihistamine medications to expand. Additionally, increased drug releases and approvals will expand the market. Additionally, growing investments in cutting-edge technologies and a spike in new markets will create more favorable conditions for the expansion of the antihistamine medicine market throughout the projection period. The rising prevalence of allergic responses and allergies globally and expanding public awareness are the main driving factors for antihistamine drugs.

Additionally, throughout the projected period, the market expansion is anticipated to be fueled by changing lifestyles and the release of novel medication therapies for treating allergic illnesses. At the same time, factors such as the patent life of pharmaceuticals, the release of generic versions, and adverse effects from therapy are anticipated to hinder market expansion throughout the projection period. Antihistaminic drugs stop the production and synthesis of chemical histamine, the primary trigger of allergic reactions. Dizziness, dry mouth, and blurred vision are side effects of antihistaminic medications. Histamine is crucial in developing localized allergic reactions by promoting vascular permeability, edema, inflammation, and smooth muscle contraction. The mechanism of action of antihistamines is the blockade of histamine type 1 (H1) receptors.

They are also employed in managing skin allergies, such as urticarial. Antihistamines are used in cases of persistent allergies or other recurring disorders and for seasonal allergies. Due to their fast alleviation and lack of adverse effects, they are favored as the first line of therapy for hay fever and other allergies. The market for antihistamine medications will also grow due to growing public and private activities to raise awareness about treating diverse allergic reactions. These elements are anticipated to fuel the growth of the global market for antihistamines. However, since many of these medications are no longer under patent, they have drawn both small and massive generic competitors, leading to fierce price competition and a decline in the market's value.

Antihistamine Drugs Market Trends

• Growing awareness about therapies related to allergies is driving the market growth.

Market CAGR for antihistamine drugs is being driven by the rising awareness about therapies related to allergies. The growing incidence of allergic responses and allergies worldwide and increased public knowledge about managing various reactions to allergens are the primary drivers impacting this market. Allergies remedies are projected to become more popular due to changing lifestyles and innovative pharmacological solutions. There is a considerable demand for these medicines, and the number of people is growing. However, patent expiry, the launch of generic forms of drugs, and the treatment of adverse reactions will likely restrain market expansion throughout the projection period. Allergic rhinitis has grown over the previous three decades, as reported by the American College of Allergy, Asthma, and Immunology—40% of the people in the United States and Europe to inhalant allergens.

Additionally, changes in lifestyle and the launch of innovative medication treatments for managing allergy illnesses are projected to drive market expansion throughout the forecast period. New product releases and FDA permission for over-the-counter switching of prescription-based nasal sprays are expected to provide attractive opportunities to major industry participants. Collaboration with regional and local players is expected to assist businesses in expanding their geographic reach and offering of goods.

Because nasal antihistamines are the most efficient and popular route of administration, the COVID-19 epidemic boosted sales. However, antihistamine sales were hindered to some amount by restricted international borders, supply delivery networks, stock shortages, and lockdown limitations. According to FMI estimates, the COVID-19 industry will rebound in the following years. This is because of the rise in the need for nose sprays and the number of people who rely on this treatment. These trends will continue in the face of healthcare changes, affecting the demand forecast.

For instance, According to WHO's White Book on Allergy 2011-2012, allergic rhinitis impacted 10%-30% of the population, whereas the average lifetime incidence of urticarial disease was above 20%. A high prevalence of allergies and a rise in incidences among youngsters are expected to increase antihistamine consumption throughout the predicted period. Therefore, it is anticipated that demand for Antihistamine Drugs will increase throughout the projection period due to the rising awareness about allergies-related therapies. Thus, driving the Antihistamine Drugs market revenue.

Antihistamine Drugs Market Segment Insights

Antihistamine Drugs Type Insights

The Antihistamine Drugs market segmentation, based on type, includes Sedating and Non-Sedating. The non-sedating category dominated the market, accounting for 51% of market revenue (USD 0.1 billion) in 2022 due to its increased preference by patients and easy availability.

Figure 1: Antihistamine Drugs Market, by Type, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Antihistamine Drugs Route of Administration Insights

The Antihistamine Drugs market segmentation, based on the route of administration, includes oral route, parenteral route, and rectal route. The oral route category generated the highest revenue of about 45% (USD 0.07 billion) in 2022 due to its increased benefits and ease of availability.

Antihistamine Drugs Indication Insights

The Antihistamine Drugs market segmentation, based on Indication, includes Allergy, Urticaria, and Dermatitis. The allergy category dominated the market, accounting for 39% of the market share (USD 0.06 billion) in 2022. Category growth is driven by the growing elderly population and the advent of innovative medication regimens used to manage allergic diseases that will accelerate market expansion.

Antihistamine Drugs End User Insights

The Antihistamine Drugs market segmentation, based on End Users, includes Hospitals, Clinics, and Pharmaceutical Companies. Hospitals dominated the market, accounting for 46% of market revenue (USD 0.07 billion) in 2022. Hospitals are in charge of giving medications that either cure or assist patients in maintaining their illnesses. As a result of their success in managing allergies affecting the nose and eyes, they have gained competence in prescribing antihistamines.

News

A recent study has discovered concrete proof that an over-the-counter antihistamine may repair the multiple sclerosis patient's destroyed protective nerve sheath. The discovery of a biomarker by researchers, which can be used to gauge a drug's efficacy, has led to the possibility of a brand-new treatment for the crippling condition. The protective myelin coating surrounding nerves is attacked by the body's immune system in the autoimmune condition multiple sclerosis (MS), resulting in irreparable damage and obstructing brain-body communication. The symptoms of demyelination, or the breakdown of myelin, can range in intensity from tingling and numbness to vision impairment and paralysis.

Antihistamine Drugs Regional Insights

By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Antihistamine Drugs market will dominate this market, owing to the increased incidence of allergic rhinitis and the increasing need for evaluating and managing allergic illnesses.

Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Antihistamine Drugs Market Share by Region 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe region’s Antihistamine Drugs market accounts for the second-highest market share. Per the European Academy of Allergies and Clinical Immunology (EAACI), allergies will impact over fifty percent of all Europeans in the next years, boosting the overall market. Further, the German Antihistamine Drugs market holds the largest market share, and the UK Antihistamine Drugs market is anticipated to grow and expand steadily in the European region during the projected timeframe.

The Asia-Pacific Antihistamine Drugs Market is expected to grow significantly during the projected timeframe. This is due to increased demand for pharmaceuticals for treating allergies and skin problems. Moreover, China’s Antihistamine Drugs market dominates the market share, and the Indian Antihistamine Drugs market is anticipated to grow rapidly in the Asia-Pacific region during the projected timeframe.

Antihistamine Drugs Key Market Players & Competitive Insights

Leading market players invested heavily in research and development (R&D) to scale up their manufacturing units and product lines, which will help the Antihistamine Drugs market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their footprint, with important market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. The Antihistamine Drugs industry must offer cost-effective and sustainable options to survive in a dynamic market.

Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the key business strategies organizations use in the Antihistamine Drugs industry to benefit customers and capture untapped market share and revenue. The Antihistamine Drugs industry has recently offered significant advantages to the medicine and service industry. Moreover, more industry participants are utilizing and adopting cutting-edge technology has grown substantially. Major players in the Antihistamine Drugs market, including Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.), are attempting to expand market share and demand by investing in research and development (R&D) operations to produce sustainable and affordable solutions.

Bayer AG is a German international pharma and biotech corporation, one of the world's leading pharma corporations. It was created in 1863 by chemical merchant Friedrich Bayer and dye firm owner Johann Friedrich Wescott. The company’s headquarters are in Leverkusen, Germany. It develops, manufactures, and distributes goods in medical treatment, dietary habits, and technologically advanced materials. Pharmaceuticals, Crop Science, Consumer Health, Animal Health, and Covestro are its business segments. The Pharmaceuticals division develops, manufactures, and markets prescription drugs for cardiac and women's medical care; specialty therapies in cancer, hematology, and ophthalmology; and medical imaging devices and contrast agents. The FDA authorized Bayer AG's Astepro to treat periodic and chronic allergies for non-prescription usage beginning in June 2021 via a temporary to non-prescription transfer. This FDA clearance has given people access to a secure, efficient nostril antihistamine without needing a healthcare practitioner.

Glenmark Pharma is a prominent creative pharmaceutical firm dedicated to improving people's lives worldwide. Gracias Saldanha created it in 1977, and it has its headquarters in Mumbai, India. They aim to uncover novel opportunities and improve the well-being of patients worldwide by creating remedies for medical gaps. They have a robust pipeline of new compounds in various stages of discovery aimed at lung disease, cancer, and skincare. Glenmark Pharma is developing cutting-edge treatments for an emerging world. Glenmark has almost 6000 employees spread throughout 80 countries, including 12 production facilities. Glenmark Pharma will introduce Ryaltris, a novel spray for the nose, in India in May 2021. Glenmark is an innovator in the pulmonary area, having been the first to launch labeled versions cheaply in India.

Key Companies in the Antihistamine Drugs market include

• 
  

  Johnson & Johnson Consumer Inc. (U.S.)

  
  


• 
  

  Sanofi (France)

  
  


• 
  

  Bayer AG (Germany)

  
  


• 
  

  Pfizer (U.S.)

  
  


• 
  

  CVS pharmacy (U.S.)

  
  


• 
  

  Merck Sharp & Dohme Corp.(U.S.)

  
  


• 
  

  Prestige Brands Holdings, Inc. (U.S.)

  
  

Antihistamine Drugs Industry Developments

March 2022: The FDA authorized Bayer AG's Astepro, used to treat periodic and chronic allergies, for non-prescription usage beginning in June 2021 via a temporary to non-prescription transfer. This FDA clearance has given people access to a secure, efficient nostril antihistamine without a healthcare practitioner.

January 2022: Glenmark Pharma will introduce Ryaltris, a novel spray for the nose, in India in May 2021. Glenmark is an innovator in the pulmonary area, having been the first to launch labeled versions cheaply in India.

February 2021: Mylan struck a contract with Pfizer in July 2019 to partner with Mylan to create Viatris, an upcoming multinational pharmaceutical firm.

Antihistamine Drugs Market Segmentation

Antihistamine Drugs Type Outlook

• 
  

  Sedating

  
  


• 
  

  Non-Sedating

  
  

Antihistamine Drugs Route of Administration Outlook

• 
  

  Oral Route

  
  


• 
  

  Parenteral Route

  
  


• 
  

  Rectal Route

  
  

Antihistamine Drugs Indication Outlook

• 
  

  Allergy

  
  


• 
  

  Urticaria

  
  


• 
  

  Dermatitis

  
  

Antihistamine Drugs End User Outlook

• 
  

  Hospitals

  
  


• 
  

  Clinics

  
  


• 
  

  Pharmaceutical Companies

  
  

Antihistamine Drugs Regional Outlook

• 
  

  North America

  
  

• 
  
  
  
  • US
  
  
  • Canada
  
  
  
  

• 
  

  Europe

  
  

• 
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America